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Abstract Niemann-Pick C disease (NPC) is an
autosomal recessive lysosomal storage disorder result-
ing from mutations in the NPC1 (95% of cases) or
NPC2 genes. Disturbance of copper homeostasis has
been reported in NPC1 disease. In this study we have
used whole-body positron emission tomography
(PET) and brain electronic autoradiography with
copper-64 (64Cu), in the form of the copper(II)
bis(thiosemicarbazonato) complex 64Cu-GTSM, to
image short-term changes in copper trafficking after
intravenous injection in a transgenic mouse model of
NPC1 disease. 64Cu-GTSM is taken up in all tissues
and dissociates rapidly inside cells, allowing moni-
toring of the subsequent efflux and redistribution of
64Cu from all tissues. Significantly enhanced retention
of 64Cu radioactivity was observed in brain, lungs and
blood at 15 h post-injection in symptomatic Npc1-/-
transgenic mice compared to wildtype controls. The
enhanced retention of 64Cu in brain was confirmed by
electronic autoradiography, particularly in the mid-
brain, thalamus, medulla and pons regions. Positron
emission tomography imaging with 64Cu in selected
chemical forms could be a useful diagnostic and
research tool for the management and understanding
of NPC1 disease.
Keywords Niemann-Pick C  Copper-64  Positron
emission tomography  Autoradiography  Copper
dyshomeostasis
Introduction
Niemann-Pick disease type C (NPC) is an autosomal
recessive lysosomal storage disorder resulting from
mutations in the NPC1 (95% of cases) or NPC2 genes.
It is characterised by the accumulation of lysosomal
cholesterol and sphingolipids giving rise to liver
dysfunction and progressive neurodegeneration,
including cerebellar atrophy leading to ataxia.
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Additionally, NPC1 disease patients have been shown
to develop Alzheimer’s disease-like neurofibrillary
pathology, which also contributes to the neurodegen-
erative process (Love et al. 1995; Auer et al. 1995;
Vanier 2010; Neufeld et al. 1999; Davies et al. 2000;
Liscum 2000). Miglustat is approved as a disease-
modifying therapy that slows disease progression
(Se´vin et al. 2007; Patterson et al. 2007).
In vitro and in vivo studies have demonstrated that
abnormal lipid metabolism in NPC1 disease is
accompanied by oxidative stress (Reddy et al. 2006;
Klein et al. 2011; Smith et al. 2009; Zampieri et al.
2009; Zhang et al. 2008; Porter et al. 2010; Zhang et al.
2014; Klinke et al. 2015). Metal dyshomeostasis
(notably copper) in NPC1 disease has been reported
and may enhance reactive oxygen species (ROS)
production and accelerate neurodegeneration (Va´z-
quez et al. 2012a, b; Sakiyama et al. 2014; Connemann
et al. 2012). The NPC1 protein may play a direct role
in normal copper metabolism since it has been
reported to mediate the incorporation of endosomal
copper into ceruloplasmin in cultured hepatocytes
(Yanagimoto et al. 2009, 2011). However, copper
imbalance in NPC1 disease may merely be a conse-
quence of aberrant lipid storage since copper and
cholesterol metabolic pathways have been shown to be
interconnected (Hung et al. 2013). Whole-brain cop-
per levels have not been measured in human brain
tissue, but were found to be decreased in NPC1 null
mice compared to healthy controls (Hung et al. 2014).
Copper content in the cerebellum was shown to be
reduced or unchanged in NPC1 null mice relative to
age-matched controls (Va´zquez et al. 2012b, Hung
et al. 2014). Copper levels in cerebrospinal fluid were
found to be decreased in a very small cohort of NPC1
patients (n = 2) as compared with healthy subjects
(Hung et al. 2014). Thus, reports on central nervous
system (CNS) copper content in NPC are sparse and
there is no clear consensus. Recently, a patient with
copper overload (thought initially to be suffering from
Wilson’s disease following the discovery of elevated
copper in a liver biospy) was correctly rediagnosed
with NPC, suggesting that tissue copper levels may be
altered in NPC1 patients (Connemann et al. 2012). An
improved understanding of copper trafficking and
tissue distribution in NPC1 disease is therefore needed
and would greatly facilitate (i) the development of new
diagnostic techniques, (ii) the elucidation of the
mechanism of disease pathogenesis and progression
and (iii) the design of more effective therapies,
including potential chelation therapy.
The increased availablity of positron emission
tomography (PET) and positron-emitting radioiso-
topes of biologically important metals has made PET
an attractive method for tracking trace metal fluxes
both in humans and animal models (Bartnicka and
Blower 2018). In this study we have explored for the
first time the value of PET with the positron-emitting
radioisotope 64Cu to image short-term copper traf-
ficking in healthyNpc1?/? versus presymptomatic and
symptomatic Npc1-/- mice (6- and 9-week-old). The
aim was to delineate potential abnormalities in copper
trafficking, both in the CNS and at whole-body level,
that might serve as a biomarker for the disorder. This
novel approach enables dynamic, live, non-invasive
investigation of Cu fluxes in the same mouse over time
and could be readily extended to humans. Intravenous
(i.v.) injection of 64Cu in the form of an ionic Cu(II)
salt gives rise to radiocopper uptake in brain and spinal
cord that is insufficient for PET imaging of uptake
processes (Andreozzi et al. 2017). Instead, here we
study copper retention and efflux of radiocopper
delivered directly to cells and tissues, bypassing
specific delivery processes by using 64Cu-GTSM
[glyoxalbis(N4-methyl-3-thiosemicarbazonato) cop-
per(II)], an uncharged, lipophilic Cu(II) complex that
displays excellent blood–brain barrier (BBB) penetra-
tion and is able to release its Cu payload efficiently and
nonselectively into cells (Torres et al. 2016; Fodero-
Tavoletti et al. 2010).
The BALB/cNctr-Npc1m1N/J (Npc1-/-) null
mutant mouse model of NPC1 disease is well-charac-
terised and displays an early-onset, severe form of
NPC1 disease, with lifespan limited to 11–12 weeks
(Shang et al. 2013; Loftus et al. 1997; Morris et al.
1982; Shio et al. 1982; Bhuvaneswaran et al. 1982).
Like NPC1 patients, NPC1 deficient (Npc1-/-) mice
develop progressive neurodegeneration characterised
by cerebral atrophy, hypomyelination and degenera-
tion of cerebellar Purkinje cells (Voikar et al. 2002). A
6-weeks of age time point was chosen as representa-
tive of the presymptomatic/early stage of the disease,
while 9-week-old mice represent the symptomatic
phase of the disease (Shang et al. 2013).
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Materials and methods
Animals
All animal experiments were performed in accordance
with the Animals (Scientific Procedures) Act, 1986
and ARRIVE guidelines, under a UK Home Office
Licence (PPL70/7459). Animals were kept in standard
conditions and fed ad libitum with regular animal feed
(PicoLab Rodent Diet 20 EXT IRR, LabDiet , US).
BALB/cNctr-Npc1m1N/J mutant mice (The Jackson
Laboratory, Charles River, UK) were maintained by
heterozygote sibling matings and genotyped to iden-
tify Npc1-/- (null) and wildtype (Npc1?/?, WT) mice
as previously described (Loftus et al. 1997). Food
intake, natural behaviour and animal body weight
were monitored weekly. At the appropriate age,
animals (all from the same source; technical repli-
cates) were assigned to groups and transported from
the Oxford laboratory to the King’s laboratory for the
imaging study and acclimatised for one week prior to
imaging. Only female mice were used for the in vivo
studies. Data acquisition and analysis were performed
without blinding.
Radiochemistry
Glyoxalbis(N4-methyl-3-thiosemicarbazone) (H2-
GTSM) was synthesised following a previously
reported procedure (Torres et al. 2016). 64Cu was
produced as previously reported on a CTI RDS 112
biomedical cyclotron at the Clinical PET Centre of St
Thomas’ Hospital in the form of 64CuCl2 in 0.1 N HCl
solution (4.8 GBq/lg). Radioactivity was measured
using a Capintec CRC-25R dose calibrator. Radio-
TLC was performed on a LabLogic Flow-Count
scanner (scan speed: 0.25 mm/s), using MERCK 60
F254 silica gel TLC plates as the stationary phase and
ethyl acetate as the mobile phase.
64CuCl2 (* 100 MBq, pH 1, 0.5 mL) was buffered
to pH 6 with a 3 M solution of sodium acetate (Sigma-
Aldrich). To this solution, 10 lg of H2-GTSM in
dimethyl sulfoxide (DMSO, 10 lL, 1 mg/mL, Sigma-
Aldrich) were added. The reaction mixture was
vortexed for 1 min and allowed to stand at room
temperature for 5–10 min. The resulting 64Cu-GTSM
solution was then loaded onto a C18 cartridge (Sep-Pak
C18 Plus Short Cartridge, 360 mg Sorbent, 55–105 lm
particle size, Waters Ltd.), previously conditioned
with ethanol and water. The sample was washed
through with water (5 mL) and ethanol (0.3 mL) and
the product collected by elution with a further 1 mL
ethanol (* 90% isolated radiochemical yield, C 95%
radiochemical purity). For intravenous administration,
64Cu-GTSMwas diluted in sterile 0.9% saline solution
(w/v) to\ 10% of total injected volume (\ 200 lL).
PET/CT imaging
Imaging experiments were performed using a nano-
Scan PET/CT scanner (Mediso Medical Imaging
Systems, Budapest, Hungary). 64Cu-GTSM-PET was
performed in 6- and 9-week-old female Npc1-/-mice
and age-matched WT controls (n = 7 in 9-week-old
Npc1-/- group, n = 6 in 6-week-old Npc1-/- group,
n = 5 in WT groups). All animals were anaesthetised
by isoflurane inhalation (3%, Vet Tech Solutions Ltd.)
for immobilisation and injected with 64Cu-GTSM
(* 15 to 20 MBq, B 200 lL) via a lateral tail vein.
Immediately after injection, mice were placed on the
scan bed in the prone position and imaged for 30 min
by PET/CT (PET: 400-600 keV energy window, 5 ns
coincidence window, 0.30 9 0.30 9 0.30 mm3 voxel
size; CT: 180 projections, 45 KVp, 0.25 9 0.25 9
0.21 mm3 voxel size). Anaesthesia was maintained
with 1.5-2% isoflurane throughout the duration of the
scan. Respiration rate and bed temperature were
monitored during image acquisition. After imaging,
mice were allowed to recover and housed overnight.
At 15 h post-injection of 64Cu-GTSM, animals were
re-scanned as described above.
PET image analysis
All PET/CT datasets were reconstructed using 3D
iterative algorithms (8 iterations, 0.25 9 0.25 9
0.25 mm3 voxel size) (Magdics et al. 2011). Inter-
crystal scatter correction was applied. All PET images
were decay-corrected to injection time prior to quan-
tification. All reconstructed datasets were analysed
using VivoQuant 1.21 software (Invicro, LLC, Bos-
ton, USA). PET and CT images were co-registered and
fixed-volume 3D ROIs (* 15 mm3) were drawn in
organs of interest to measure 64Cu concentration. The
sum of activity (MBq) in the organ ROI was divided
by the sum of activity (MBq) in the whole-body ROI
(excluding tail) at the time of injection and the
resulting percentage [% injected dose (ID)] was
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normalised by the volume of the organ ROI to express
64Cu uptake as %ID/mL. Global and regional concen-
trations of 64Cu in the brain were measured using a
mouse brain atlas NM/CT module (Invicro, LLC).
Ex vivo biodistribution
After the 15 h imaging time point, all mice were culled
and dissected. Organs of interest were explanted,
weighed and gamma-counted (LKB Wallac 1282) to
measure 64Cu concentration in each organ as %ID/g.
The sum of whole-body counts (excluding tail) and
excreted activity (urine and faeces) was considered as
the total ID.
Ex vivo brain autoradiography
After dissection and gamma counting, brain tissue was
cryopreserved in 30% sucrose solution for * 6 h,
flash-frozen in isopentane (Sigma-Aldrich) and stored
at - 80 C overnight. Sagittal 10 lm brain sections
were then cut using a Bright 5040 cryotome and thaw-
mounted onto Superfrost PLUS glass microscope
slides (Menzel-Glaser, Thermo Scientific), which
were then exposed to a storage phosphor screen
(PerkinElmer, Super Resolution, 12.5 9 25.2 cm) for
15 h. Finally, the screen was scanned using a Typhoon
8600 scanner (Molecular Dynamics) and the resulting
autoradiographs were analysed with OptiQuant 5.0
(PerkinElmer) and ImageJ (NIH).
Statistical analysis
In exploratory studies such as this where expected
difference size and variance is unknown, the number
of animals per group in our imaging experiments is
typically estimated using a two-tailed T test with a
confidence interval of 95% and a power of 80%. For a
signal-to-noise ratio of 2 ± 1 versus 7.5 ± 4.5 after
injection, to detect a nominal difference of 5.5 for a
nominal standard deviation of 4.5, 8 animals per group
need to be studied. Our group size was determined by
approaching this ideal as closely as resources allowed
and with a pre-set minimum of 3 per group, while
avoiding breeding unnecessarily large numbers. Sam-
ple size differences are the result of sorting after
genotyping; data from all available animals were
included in the analysis. All data are reported as
mean ± standard deviation (SD). Statistical analysis
was performed using GraphPad Prism 5 (GraphPad
Software Inc.). Significance of differences between
groups was estimated with two-tailed Student’s t tests
and Mann–Whitney U tests. Two-way repeated mea-
sures ANOVA with post hoc analyses using the
Bonferroni multiple comparison correction was used
to determine statistically significant differences
between Npc1-/- mice and WT controls at different
imaging time-points. No data were defined as outliers.
Results
PET/CT imaging
In order to investigate short-term (\ 15 h) copper
trafficking in NPC1 disease, Npc1-/- mice at 6 and
9 weeks of age and age-matched WT controls were
intravenously injected with 64Cu-GTSM and live
imaged from 0 to 30 min and from 15 to 15.5 h
post-injection.
Figure 1, as an example, depicts the in vivo
biodistribution of 64Cu in 6- and 9-week-old
Npc1-/- mice and WT controls at 30 min and 15 h
after injection At 30 min post-injection of the tracer
the images were qualitatively similar for all four
groups (6 week-old Npc1-/-, 6 week-old WT,
9 week-old Npc1-/-, 9 week-old WT), showing that
64Cu accumulated predominantly in the lungs, heart
and to a lesser extent in the liver, intestines, kidneys,
and brain. In addition, the images showed marked
uptake in adrenal glands and spinal cord, organs that
were not harvested ex vivo. At 15 h, the images for all
four groups were also qualitatively similar but the
activity in the lungs, kidneys, heart and adrenal glands
was visibly diminished compared to 30 min, while
uptake in brain, spinal cord and liver was not visibly
different.
These visual impressions were confirmed by quan-
titative image analysis, fromwhich uptake values were
obtained in organs of interest (Fig. 2). Although the
volume of smaller organs is overestimated by the
method used to define ROIs because of the partial
volume effect (and consequently the %ID/mL values
may be underestimated), these values were similar to
those obtained from ex vivo biodistribution in 9-week-
old mice at 15 h (vide infra). The %ID/mL values for
lung derived from PET were much less than the %ID/g
values derived from ex vivo organ counting because
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the density of lung is much less than 1.0 g/mL, unlike
other tissues. The standard deviations of the PET-
derived uptake values were, however, higher than
those of the values derived from ex vivo organ
counting. Consequently, while the uptake in hearts,
lungs and brains of 9-week-old Npc1-/- mice was
higher than that in WT mice (by 42, 43 and 29%
respectively) whether measured by PET or ex vivo
organ counting, the differences measured by PET did
not reach statistical significance. Uptake in spinal
cord, as measured by PET, was also higher in 9-week-
old Npc1-/- mice than in their WT counterparts (by
39%).
PET imaging allows investigation of the dynamics
of the tracer distribution during the 15 h post injection.
Figure 3 shows significant net efflux of radioactivity
between 30 min and 15 h from heart (a percentage
change in radioactivity of - 40 ± 26% in Npc1-/-
mice, - 47 ± 19% in WT mice at 6 weeks;
- 47 ± 11% in Npc1-/- mice, - 51 ± 10% in WT
mice at 9 weeks), lungs (- 55 ± 21% in Npc1-/-
mice, - 59% ± 13% in WT mice at 6 weeks;
- 42 ± 33% in Npc1-/- mice, - 53 ± 9% in WT
mice at 9 weeks) and kidneys (- 48 ± 10% in
Npc1-/- mice, - 53 ± 12% in WT mice at 6 weeks;
- 54 ± 11% in Npc1-/- mice, - 56 ± 8% in WT
mice at 9 weeks). The liver, by contrast, showed a net
influx of radioactivity between 30 min and 15 h
(? 48 ± 21% in Npc1-/- mice, ? 20% ± 38% in
WT mice at 6 weeks; ? 43 ± 45% in Npc1-/- mice,
Fig. 1 Representative sagittal and coronal views of PET/CT
images (maximum intensity projection, MIP) of 6-week-old
(top) and 9-week-old (bottom) female WT (left) and Npc-/-
(right) mice at 30 min (left) and 15 h (right) post-injection of
64Cu-GTSM. PET images in all four groups were visually
similar, showing high accumulation of 64Cu radioactivity in the
heart (H), lungs (Lu), liver (L), kidneys (K), adrenals, intestines
(I) and brain (B) at 30 min after injection of the tracer in all
mice. The spinal cord was also clearly visible. While 64Cu
accumulation decreased in the heart, lungs, adrenals and kidneys
between 30 min and 15 h, the concentration of radiocopper in
the liver and intestines increased. Brain uptake of 64Cu remained
relatively constant over time. All MIPs were scaled to 0–1%ID/
mL (min) and 40%ID/mL (max)
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? 32 ± 52% in WT mice at 9 weeks). However, this
time-dependent change in liver activity was subject to
large variation in all four groups, ranging from? 77 to
- 50% in individual animals. The % efflux/influx in
these organs of Npc1-/- mice was not significantly
different to that in WT mice.
In marked contrast to heart, lungs, liver and
kidneys, the changes in radioactivity levels in the
CNS between 30 min and 15 h (Fig. 4) were minor
and not significant, showing that activity accumulated
by 30 min was retained; indeed, there was a small net
increase of activity in the brain during the period
(10 ± 10% in Npc1-/- mice, 8 ± 9% in WT mice at
6 weeks; 17 ± 17% in Npc1-/- mice, 11 ± 12% in
WT mice at 9 weeks). Similarly, in spinal cord there
was no significant net efflux; indeed a marginal (non-
statistically significant) net influx between 30 min and
15 h (? 6 ± 10% inNpc1-/-mice,? 1 ± 6% inWT
mice at 6 weeks; 0 ± 7% in Npc1-/- mice,
? 2 ± 9% in WT mice at 9 weeks).
Despite the limitations of resolution of PET (of the
order of 0.5–0.7 mm), imaging and quantitative
analysis of the distribution of radioactivity within the
brain was possible. Because of its low positron energy,
64Cu provides superior resolution images compared to
many other radionuclides used for PET. The anatom-
ical definition of brain regions was based on mapping
of the images onto a three-dimensional digital mouse
brain atlas. Figure 5 shows examplar images of brains
from all four groups. Inhomogenous distribution of
radioactivity within the brain was evident in all four
groups both at 30 min and 15 h, and it is likely that the
inhomogeneity is visually underestimated because of
limited resolution of the PET scanner.
The results of quantitative regional analysis
mapped onto the mouse brain atlas are shown in
Fig. 6. The increased global brain uptake of radioac-
tivity in Npc1-/- mice compared to WT mice was
apparent in all anatomical regions examined and was
statistically significant in the 9-week-old group. In all
four groups, the regions of highest activity at both
30 min and 15 h were thalamus and midbrain and the
regions of lowest activity were the cortex, olfactory
bulb and cerebellum. In all groups, there were no
significant changes in distribution among brain
regions between 30 min and 15 h.
Post-hoc evaluation revealed significant differ-
ences in 64Cu concentration in specific brain regions
between the Npc1-/- and WT 9-week-old groups at
both imaging time-points (Fig. 6). At 30 min after
injection, Npc1-/- mice exhibited significantly
greater 64Cu levels than their WT littermates in the
midbrain (p\ 0.01), thalamus (p\ 0.05) and white
matter (p\ 0.05); these significant differences per-
sisted at 15 h in midbrain (p\ 0.05) and thalamus
(p\ 0.05). In 6-week-old mice, the same trends were
observed but regional differences did not reach
statistical significance.
To show that these differences in 64Cu concentra-
tion in the CNS between Npc1-/- andWT 9-week-old
mice were not affected by subtle differences in body
weight between groups, 64Cu uptake was also
expressed as standardised uptake values (SUV,1 which
implicitly corrects for body weight). SUV measure-
ments revealed significantly higher 64Cu concentra-
tion in the spine (p\ 0.01; 30 min and 15 h) and brain
(p\ 0.01; 15 h) of 9-week old Npc1-/- mice, as well
as enhanced 64Cu retention in midbrain and thalamus
(p\ 0.05; 30 min) and thalamus and hypothalamus
(p\ 0.05; 15 h) when compared to controls.
Ex vivo biodistribution
In both Npc1-/- and WT 9-week old mice, ex vivo
biodistribution of radioactivity at 15 h post-injection
Fig. 2 Uptake (%ID/mL) of 64Cu in organs distinguishable on
PET scans of 9-week-old Npc1-/- (red bars, n = 7) and WT
(blue bars, n = 5) mice 15 h post injection of 64Cu-GTSM,
determined by quantitative image analysis. Error bars repre-
sent ± one standard deviation. The same trends are evident as in
Fig. 7 but the standard deviations are larger because of the
intrinsic limitations of PET region of interest quantification and
volume determination
1 %ID/g for the specified tissue divided by the %ID for the
whole body, excluding tail.
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of 64Cu-GTSM was measured by counting and
weighing harvested organs post mortem after the
imaging. A high retention ([ 20%ID/g) was found in
the lungs, liver, heart, intestines and brain (Fig. 7),
similar to that observed previously in WT mice
(Andreozzi et al. 2017; Torres et al. 2016). Signifi-
cantly enhanced retention was observed in blood (by
78%, p = 0.0043), lungs (by 73%, p = 0.005) and
brain (by 35%, p = 0.03) of Npc1-/- mice compared
to WT mice (Fig. 7). Activity in urine was very low at
this late time point but was significantly higher in
Npc1-/- than in WT mice (p = 0.0015). Differences
in other tissues were not statistically significant.
Fig. 3 Dynamics of
radioactivity uptake and
efflux in heart, lungs, kidney
and liver, showing uptake of
64Cu at 30 min and 15 h
post injection of 64Cu-
GTSM in 6-week-old (left)
and 9-week-old (right)
Npc1-/- (black, n = 7) and
WT (grey, n = 5) mice.
Error bars represent ± one
standard deviation
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Ex vivo brain autoradiography
In order to generate high-resolution maps of the
distribution of 64Cu within brain tissue, sagittal brain
sections of Npc1-/- mice and WT controls sacrificed
at 15 h post-injection of 64Cu-GTSM were imaged by
phosphor imaging autoradiography. Images in Fig. 8
show the regional distribution of 64Cu in representa-
tive sagittal brain slices of Npc1-/- mice and WT
controls at 15 h after injection of the tracer as
measured by digital autoradiography. These ex vivo
autoradiographs reflect the heterogeneous distribution
of radioactivity within the brain, and the globally
higher accumulation of 64Cu in the brains of 9-week-
old Npc1-/- mice compared to age-matched WT
controls, that were detected by PET imaging. Themost
prominent radioactive hotspots in the Npc1-/- brain
autoradiographs were found in the midbrain, thalamus,
medulla and pons regions.
Discussion
In this study, we have investigated in vivo copper
trafficking in a mouse model of NPC1 disease at
presymptomatic (6 weeks) and symptomatic
(9 weeks) stages of the disorder by PET imaging
using 64Cu-GTSM in order to identify any measurable
changes in copper efflux and distribution associated
with the pathology. We have focused particularly on
the delineation of copper trafficking within the CNS
since transition metal imbalance has been linked to
enhanced oxidative stress in NPC1 disease and is
therefore proposed to contribute to the
Fig. 4 Dynamics of radioactivity uptake and efflux in brain and
spinal cord, showing uptake of 64Cu at 30 min and 15 h post
injection of 64Cu-GTSM in 6-week-old (left) and 9-week-old
(right) Npc1-/- (black, n = 7) andWT (grey, n = 5) mice. Error
bars represent ± one standard deviation
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neurodegenerative process characteristic of this dis-
order (Va´zquez et al. 2011, 2012a; Porter et al. 2010).
For this reason, we used 64Cu-GTSM as a vehicle to
deliver intravenously-administered radioactive copper
into the CNS and release it within cells, allowing
subsequent monitoring of its efflux and trafficking.
This mode of administration bypasses the innate
absorption phase of endogenous copper metabolism
and facilitates rapid deposition of radiocopper within
the CNS. However, the fate of orally administered
radiocopper should also be evaluated by PET in future
studies in order to detect any potential abnormalities in
the gastrointestinal absorption and subsequent trans-
port of copper that might be associated with NPC1
disease.
As expected from a previous study (Torres et al.
2016), 64Cu-GTSM rapidly delivered radiocopper to
all major organs after injection, including the heart,
lungs, liver, intestines, kidneys, brain and spinal cord.
The decrease of radioactivity in the heart, lungs and
Fig. 5 Representative coronal and sagittal PET/CT MIP
images illustrating 64Cu distribution in the brains of 6-week-
old (upper panel) and 9-week-old (lower panel) WT controls left
and age-matched Npc1-/-mice (right) at 30 min (top) and 15 h
(bottom) post-injection of 64Cu-GTSM. Nine-week-old
Npc1-/- mice exhibited higher brain 64Cu accumulation than
their WT littermates at all imaging time-points. All MIPs were
scaled to 0–2%ID/mL (min) and 20%ID/mL (max)
123
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kidneys between 30 min and 15 h, and the accompa-
nying accumulation in the liver and intestines, reflects
excretion of radiocopper particularly via the biliary
system. Significant increases in uptake (whether
expressed as %ID/g or SUV) of 64Cu in several
tissues were found in Npc1-/- compared to WT
animals. However, despite previous studies reporting
increased copper content in the liver of Npc1 deficient
mice compared to control animals (Va´zquez et al.
2011; Argu¨ello et al. 2014; Hung et al. 2014), no
significant differences in hepatic 64Cu concentration
were found between Npc1-/- andWT groups at either
6 or 9 weeks of age. This discrepancy might be
explained on the basis of differences between long-
term (total copper content measurements) and short-
term (acute trafficking studies described here) copper
biodistribution; the previously reported increased
copper levels in the liver of Npc1-/- mice are the
result of prolonged accumulation of dietary copper in
this organ, and might therefore not be measurable by
acute PET measurements.
As previously observed both in healthy mice and
models of Alzheimer’s disease (Torres et al. 2016;
Fodero-Tavoletti et al. 2010), both brain and spinal
cord showed surprisingly high radiocopper sequestra-
tion. The negligible clearance of 64Cu radioactivity
from brain and spinal cord between 30 min and 15 h
compared to other tissues, in all groups, might be
caused by a particularly high metabolic demand for
copper of the CNS and/or less active or absent copper
efflux mechanisms compared to other tissues.
Fig. 6 Top: Regional brain distribution of 64Cu in 6-week-old
(left panels) and 9-week-old (right panels) Npc1-/- mice and
age-matched controls at 30 min (top panels) and 15 h (bottom
panels) post-injection of 64Cu-GTSM. Data are mean [n = 6-7
Npc1-/-, n = 5 WT)] ± SD. Statistically significant differ-
ences from healthy controls were evident in the 9-week-old
groups and are indicated by * (p\ 0.05) and ** (p\ 0.01)
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Differences in whole-brain and spinal cord 64Cu
concentration between presymptomatic (6-week-old)
Npc1-/- mice and age-matched controls were
observed but did not reach statistical significance.
However, the difference persisted and increased with
age such that at 9 weeks, Npc1-/- mice exhibited
significantly higher 64Cu concentration (whether
expressed as %ID/g or SUV) than WT controls at
both 30 min and 15 h post-injection of 64Cu-GTSM.
Interestingly, these differences in brain and spinal cord
64Cu concentration between the Npc1-/- and WT
groups were associated with a significant decrease in
brain 64Cu concentration with age in these organs in
WT mice.
Reduced total copper content observed in the
cerebellum of NPC1-deficient mice (Hung et al.
2014) contrasts with the increased acute 64Cu
uptake/retention in our experiments, highlighting the
importance of measuring both long-term chronic total
copper accumulation and its short-term trafficking.
Copper levels in the remaining brain regions have not
previously been reported.
The finding of significantly higher 64Cu concentra-
tion in the blood of Npc1-/- mice 15 h post injection
than their WT littermates is in agreement with
previous research revealing increased copper content
in blood plasma in presymptomatic and symptomatic
Npc1-/-mice compared to healthy controls (Va´zquez
et al. 2012b; Hung et al. 2014). This elevated blood
64Cu concentration (by 78%) in Npc1-/- mice would
not fully account for the enhanced accumulation of
64Cu (by 35%) in their brains and spinal cords, because
blood radioactivity is much lower than that of brain
and spinal cord, and blood content in these tissue is not
high. Elevation of plasma copper in NPC1-deficient
mice has been associated with an increase in plasma
ceruloplasmin levels, which might indicate a higher
rate of synthesis/secretion of this protein in NPC1
disease (Va´zquez et al. 2012b; Hung et al. 2014).
NPC1 belongs to a family of proteins termed RND
permeases that have been implicated in bacterial
systems to play a role in metal ion transport (Kim et al.
2011). NPC1 may therefore directly play a role in
copper export from the lysosome (Yanagimoto et al.
2009, 2011) or indirectly affect other transport
systems involved in copper transport/homeostasis
(Argu¨ello et al. 2014) and merits further investigation.
Additional studies are needed to determine whether
plasma 64Cu is inserted into ceruloplasmin or bound to
other plasma proteins (e.g. albumin, transcuprein), and
whether increased blood 64Cu concentration in
Npc1-/- mice can be detected at earlier time-points
after injection of the tracer (\ 15 h). The relationship
Fig. 7 Radioactivity accumulation/retention in harvested
organs of 9-week-old Npc1-/- (black bars, n = 7) and WT
(white bars, n = 5) mice, 15 h after i.v. injection of 64Cu-
GTSM, determined by ex vivo gamma counting. Error bars
represent one standard deviation; **p\ 0.01; *p\ 0.05
Fig. 8 Ex vivo autoradiographs from representative sagittal
brain sections of 9-week-old Npc1-/- (top) and WT control
(bottom) mice sacrificed at 15 h post-injection of 64Cu-GTSM.
The main radioactive hotspots in the Npc1-/- brain autoradio-
graphs were located in the thalamus, midbrain, cerebellum,
medulla and pons areas. TH thalamus, M midbrain, CE
cerebellum, ME medulla, P pons
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between blood copper concentration and disease
severity and progression also needs to be evaluated
in order to determine the potential of this parameter as
an early diagnostic marker of NPC1 disease.
Conclusions
This study has demonstrated the potential of 64Cu-
GTSM-PET as a tool to identify alterations in copper
metabolism associated with NPC disease processes,
particularly within the CNS. 64Cu-GTSM-PET
revealed significantly increased 64Cu concentration
in the brains and spinal cords of symptomatic Npc1-/-
mice compared to healthy controls at both 30 min and
15 h post-injection of the tracer. Symptomatic
Npc1-/- mice exhibited significantly higher 64Cu
concentration in blood than their WT littermates at
15 h after injection. Despite the statistical power of
this study being insufficient to confirm some of the
subtler changes in copper trafficking, the origin of
these metabolic abnormalities along with their rela-
tionship with disease severity and progression merit
further investigation. Due to the inability of NPC1-
deficient mouse models to mimic the phenotypic
variability of human NPC1 disease, PET imaging of
copper trafficking should additionally be performed in
human subjects in order to delineate any potential
abnormalities that could be used to assess the status of
the disease and potentially monitor response to
treatment.
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